Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Novavax Inc (NVAX)

Novavax Inc (NVAX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,692,928
  • Shares Outstanding, K 74,484
  • Annual Sales, $ 475,600 K
  • Annual Income, $ -418,260 K
  • 60-Month Beta 1.62
  • Price/Sales 37.16
  • Price/Cash Flow N/A
  • Price/Book 24.99
Trade NVAX with:

Options Overview

Details
  • Implied Volatility 75.98%
  • Historical Volatility 67.45%
  • IV Percentile 6%
  • IV Rank 13.02%
  • IV High 165.67% on 01/28/21
  • IV Low 62.55% on 06/24/21
  • Put/Call Vol Ratio 0.71
  • Today's Volume 25,843
  • Volume Avg (30-Day) 27,213
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 147,791
  • Open Int (30-Day) 138,532

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -4.04
  • Number of Estimates 4
  • High Estimate -3.12
  • Low Estimate -5.04
  • Prior Year -3.21
  • Growth Rate Est. (year over year) -25.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
216.75 +9.59%
on 08/19/21
277.80 -14.49%
on 09/08/21
+2.97 (+1.27%)
since 08/17/21
3-Month
170.51 +39.31%
on 06/18/21
277.80 -14.49%
on 09/08/21
+57.65 (+32.05%)
since 06/17/21
52-Week
76.59 +210.14%
on 11/10/20
331.68 -28.38%
on 02/09/21
+122.03 (+105.64%)
since 09/17/20

Most Recent Stories

More News
Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its participation...

NVAX : 237.54 (+0.11%)
Pfizer, Moderna Support COVID Vaccine Booster Before FDA Meet

Amid rising coronavirus cases, PFE and MRNA are trying to make booster doses of their COVID-19 vaccine available for US citizens. An FDA meeting is scheduled tomorrow to discuss Comirnaty's booster dose....

AZN : 55.56 (-1.84%)
JNJ : 164.75 (-0.28%)
PFE : 43.89 (-1.30%)
MRNA : 430.05 (-2.41%)
NVAX : 237.54 (+0.11%)
BNTX : 359.18 (-3.61%)
Novavax (NVAX) Gains As Market Dips: What You Should Know

Novavax (NVAX) closed at $234.29 in the latest trading session, marking a +0.2% move from the prior day.

NVAX : 237.54 (+0.11%)
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients - Financial News Media

Palm Beach, FL - September 14, 2021 – FinancialNewsMedia.com News Commentary – All across the globe, innumerable scientists are looking to beat COVID-19... the two main paths are to find better vaccines...

BIOV.CN : 0.540 (+24.14%)
BVAXF : 0.4236 (+26.07%)
SRNE : 8.25 (+2.10%)
BNTX : 359.18 (-3.61%)
CYDY : 2.0100 (+22.56%)
NVAX : 237.54 (+0.11%)
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients

/PRNewswire/ --  - All across the globe, innumerable scientists are looking to beat COVID-19… the two main paths are to find better vaccines and to utilize better treatments. As with most viruses, developing...

BIOV.CN : 0.540 (+24.14%)
BVAXF : 0.4236 (+26.07%)
SRNE : 8.25 (+2.10%)
BNTX : 359.18 (-3.61%)
CYDY : 2.0100 (+22.56%)
NVAX : 237.54 (+0.11%)
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?

Smart Beta ETF report for EUSA

EUSA : 85.97 (-0.74%)
MRNA : 430.05 (-2.41%)
NVAX : 237.54 (+0.11%)
ENPH : 160.89 (+2.61%)
VTI : 229.04 (-0.80%)
ITOT : 101.57 (-0.78%)
Novavax (NVAX) Stock Surges YTD as COVID Vaccine Advances Well

Upon approval and successful commercialization, Novavax's (NVAX) COVID-19 vaccine should reap huge revenues. The company's other pipeline candidates also show promise.

AZN : 55.56 (-1.84%)
PFE : 43.89 (-1.30%)
MRNA : 430.05 (-2.41%)
NVAX : 237.54 (+0.11%)
Novavax (NVAX) Begins Clinical Study on COVID/Flu Combo Jab

Novavax (NVAX) starts enrolling patients in a phase I/II study to evaluate a combination of its COVID vaccine and seasonal influenza vaccine.

AZN : 55.56 (-1.84%)
PFE : 43.89 (-1.30%)
MRNA : 430.05 (-2.41%)
NVAX : 237.54 (+0.11%)
Novavax to Participate in Upcoming September Conferences

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor...

NVAX : 237.54 (+0.11%)
The Vaccine Revolution Portfolio (MRNA, PFE, JNJ, NVAX, BNTX, AZN, DYAI)

JNJ : 164.75 (-0.28%)
SRNE : 8.25 (+2.10%)
DYAI : 5.37 (+1.90%)
NVAX : 237.54 (+0.11%)
MRNA : 430.05 (-2.41%)
PFE : 43.89 (-1.30%)
BNTX : 359.18 (-3.61%)
AZN : 55.56 (-1.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as...

See More

Key Turning Points

3rd Resistance Point 252.42
2nd Resistance Point 245.71
1st Resistance Point 241.62
Last Price 237.54
1st Support Level 230.83
2nd Support Level 224.12
3rd Support Level 220.04

See More

52-Week High 331.68
Last Price 237.54
Fibonacci 61.8% 234.24
Fibonacci 50% 204.14
Fibonacci 38.2% 174.04
52-Week Low 76.59

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar